Verseon - About the company
Verseon is a public company based in Fremont (United States), founded in 2002 by Adityo Prakash, David Kita and Eniko Fodor. It operates as a Physics and AI-driven precision engineering of novel disease treatments. Verseon has raised $19.1M in funding.
Company Details
Physics and AI-driven precision engineering of novel disease treatments. This company is dedicated to redefining disease treatment through advanced drug design and development. They engineer new treatments atom by atom, focusing on delay, prevention, and treatment of major human diseases. Their approach involves breakthrough molecular physics modeling, integrated in vitro and in vivo validation, AI optimization, and computer-directed synthesis. They are developing first-in-class drug candidates that cannot be found through other methods, with a pipeline spanning cardiometabolic diseases and cancers. Their programs aim to offer life-changing treatment options, including solutions for heart attacks, strokes, diabetic vision loss, multidrug-resistant cancers, and aggressive solid-tumor metastasis. They leverage deep quantum modeling and AI, including their VersAI technology, to accelerate drug discovery and overcome data scarcity. This innovative approach positions them as a leader in AI innovation within the pharmaceutical industry, transforming medicine through precision-engineered solutions.
- Website
- www.verseon.com/
- Email ID
- *****@verseon.com
- Registered Address
- Fremont, California
Key Metrics
Founded Year
2002
Location
Fremont, United States
Stage
Public
Total Funding
$19.1M in 7 rounds
Latest Funding Round
Investors
Employee Count
60 as on Dec 31, 2022
Investment & Acquisitions
Exit Details
Public
Legal entities associated with Verseon
Verseon is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
Verseon Corporation CIN: 261169038 , Belgium, Active | Dec 26, 999 | - | 60 (As on Dec 31, 2022) | - |
Verseon's IPO details
Verseon got listed on May 07, 2015.
Click here to take a look at Verseon's IPO in detail
Sign up to download Verseon's company profile
Verseon's funding and investors
Verseon has raised a total funding of $19.1M over 7 rounds. Its first funding round was on Oct 31, 2005. Verseon has 1 institutional investor.
Here is the list of recent funding rounds of Verseon:
Filter this list
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Apr 24, 2019 | 1984580 | Post IPO | 5693657 | 6618848 | 9313539 | 9459828 |
May 13, 2015 | 8377586 | Post IPO | 7654617 | 6293297 | 8868791 | 1280092 |
Nov 10, 2014 | 9892031 | Series B | 9254110 | 4562400 | 9942757 | 4432554 |
View details of Verseon's funding rounds and investors
Verseon's founders and board of directors
Founder? Claim ProfileHere are the details of Verseon's key team members:
- Adityo Prakash: Co-Founder & CEO of Verseon and founder of 1 other company. Contact Info: 1 email address
- David Kita: VP of R&D / Cofounder • Drug Discovery • Translational Research • Clinical Development of Verseon. Contact Info: 1 email address
- Eniko Fodor: Co-Founder & COO of Verseon. Contact Info: 1 email address
View details of Verseon's Founder profiles and Board Members
Verseon's employee count trend
Verseon has 60 employees as of Dec 22. The total employee count is 3.0% more than what it was in Dec 21. Here is Verseon's employee count trend over the years:
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Verseon's Investments and acquisitions
Verseon has acquired Edammo. Verseon has not made any investments as of now.Reports related to Verseon
Here is the latest report on Verseon's sector:
News related to Verseon
Media has covered Verseon for 1 event in last 1 year, It was about company updates.
•
•
Verseon and NeuTherX Announce Partnership to Enhance Drug DevelopmentBenzinga•Jul 30, 2024•Verseon, NeuTherX
•
•
Drug-discovery pioneer Verseon delivers breakthrough once predicted by Steve JobsPR Newswire•May 16, 2022•Verseon, steve
•
•
•
•
Verseon Showcases Candidates for Next-Generation Diabetic Eye Disease DrugsBusiness Wire•Jun 04, 2019•Verseon
•
Verseon Presents Oral Drug Candidate for Diabetic Eye Disease That Could Replace Eye InjectionsBusiness Wire•Apr 30, 2019•Verseon
•
Are you a Founder ?
FAQs about Verseon
Explore our recently published companies
- Capitalsfb.com - 2018 founded, Unfunded company
- Specule - Delhi based, 2017 founded, Unfunded company
- Tech Hive Technologies - Rawalpindi based, 2017 founded, Unfunded company
- Wise Accelerate - Hanoi based, 2021 founded, Unfunded company
- AblyCon Global - Bengaluru based, 2014 founded, Unfunded company
- Civoya - 2025 founded, Unfunded company